Citations (103)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Gaia Sampogna, Filippo Caraci, Claudia Carmassi, Bernardo Dell’Osso, Silvia Ferrari, Giovanni Martinotti, Gabriele Sani, Gianluca Serafini, Maria Salvina Signorelli & Andrea Fiorillo. (2023) Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper. Expert Opinion on Pharmacotherapy 24:14, pages 1511-1525.
Read now
Read now
Alonso Montoya, Robert Bruins, Martin A Katzman & Pierre Blier. (2016) The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatric Disease and Treatment 12, pages 541-557.
Read now
Read now
Roger S. McIntyre, Rana Fayyad, Joan A. Mackell & Matthieu Boucher. (2016) Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. Current Medical Research and Opinion 32:3, pages 587-599.
Read now
Read now
Michael E. Thase, Rana Fayyad, Ru-fong J. Cheng, Christine J. Guico-Pabia, Jonathan Sporn, Matthieu Boucher & Karen A. Tourian. (2015) Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Current Medical Research and Opinion 31:4, pages 809-820.
Read now
Read now
Rob Allen, Uma Sharma & Suna Barlas. (2014) Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. Journal of Pain Research 7, pages 339-351.
Read now
Read now
Pierre-Michel Llorca, Christophe Lançon, Mélanie Brignone, Benoît Rive, Samir Salah, Larry Ereshefsky & Clément Francois. (2014) Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Current Medical Research and Opinion 30:12, pages 2589-2606.
Read now
Read now
Susan G Kornstein, Roger S McIntyre, Michael E Thase & Matthieu Boucher. (2014) Desvenlafaxine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 15:10, pages 1449-1463.
Read now
Read now
Kevin Ryan Connolly & Michael E Thase. (2012) Emerging drugs for major depressive disorder. Expert Opinion on Emerging Drugs 17:1, pages 105-126.
Read now
Read now
R. J. Cheng, C. DuPont, D. F. Archer, W. Bao, J. Racketa, G. Constantine & J. H. Pickar. (2012) Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric 16:1, pages 17-27.
Read now
Read now
Chi-Un Pae. (2011) Desvenlafaxine in the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 12:18, pages 2923-2928.
Read now
Read now
C.J. Guico-Pabia, Q. Jiang, P.T. Ninan & M.E. Thase. (2011) Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders. Current Medical Research and Opinion 27:9, pages 1815-1826.
Read now
Read now
A. H. MacLennan. (2011) HRT in difficult circumstances: are there any absolute contraindications?. Climacteric 14:4, pages 409-417.
Read now
Read now
Bojana Perović, Marija Jovanović, Branislava Miljković & Sandra Vezmar. (2010) Getting the balance right: Established and emerging therapies for major depressive disorders. Neuropsychiatric Disease and Treatment 6, pages 343-364.
Read now
Read now
Alice I Nichols, Karen A Tourian, Susanna Y Tse & Jeffrey Paul. (2010) Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor. Expert Opinion on Drug Metabolism & Toxicology 6:12, pages 1565-1574.
Read now
Read now
Ho-Jun Seo, Manmohandeep Singh Sohi, Ashwin A. Patkar, Prakash S. Masand & Chi-Un Pae. (2010) Desvenlafaxine Succinate: A Newer Antidepressant for the Treatment of Depression and Somatic Symptoms. Postgraduate Medicine 122:1, pages 125-138.
Read now
Read now
Sujana Reddy, Cecelia Kane, Bruno Pitrosky, Jeff Musgnung, Philip T. Ninan & Christine J. Guico-Pabia. (2010) Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Current Medical Research and Opinion 26:1, pages 139-150.
Read now
Read now
Maria Teresa C Lourenco & Sidney H Kennedy. (2009) Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 5, pages 127-136.
Read now
Read now
Chi-Un Pae. (2009) Desvenlafaxine: a new antidepressant or just another one?. Expert Opinion on Pharmacotherapy 10:5, pages 875-887.
Read now
Read now
Jayesh Kamath & Venkatesh Handratta. (2008) Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Review of Neurotherapeutics 8:12, pages 1787-1797.
Read now
Read now
Articles from other publishers (84)
Pratap Chokka, Ash Bender, Stefan Brennan, Ghalib Ahmed, Marc Corbière, David J. A. Dozois, Jeff Habert, John Harrison, Martin A. Katzman, Roger S. McIntyre, Yang S. Liu, Karen Nieuwenhuijsen & Carolyn S. Dewa. (2023) Practical pathway for the management of depression in the workplace: a Canadian perspective. Frontiers in Psychiatry 14.
Crossref
Crossref
Teresa Wiesinger, Stefanie Kremer, Tom Bschor & Christopher Baethge. (2023)
Antidepressants and quality of life in patients with major depressive disorder – Systematic review and meta‐analysis of double‐blind, placebo‐controlled
RCTs
. Acta Psychiatrica Scandinavica 147:6, pages 545-560.
Crossref
Crossref
Ravi Bansal, David J. Hellerstein, Siddhant Sawardekar, Ying Chen & Bradley S. Peterson. (2023) A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorder. Psychiatry Research: Neuroimaging 331, pages 111634.
Crossref
Crossref
Qian Zhao, Bingbing Fu, Nan Lyu, Xiangdong Xu, Guangbiao Huang, Yunlong Tan, Xiufeng Xu, Xuehua Zhang, Xueyi Wang, Zhiqiang Wang, Keqing Li, ZhenYu Hu, Hengfen Li, Hongbo He, Shuang Li, Jingyuan Zhao, Ruifeng He, Hua Guo, Yi Li, Lehua Li, Chuang Yang, Shaohong Zou, Bo Wei, Wenqiang Wang, Ce Chen, Zheng Lu, Shunqiang He, Qian Wang, Jinghua Zhao, Xiaoyue Pan, Zhenyu Pan, Junqing Li & Gang Wang. (2023) A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. Journal of Affective Disorders 329, pages 72-80.
Crossref
Crossref
Stefanie Kremer, Teresa Wiesinger, Tom Bschor & Christopher Baethge. (2023) Antidepressants and Social Functioning in Patients with Major Depressive Disorder: Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs. Psychotherapy and Psychosomatics 92:5, pages 304-314.
Crossref
Crossref
Sungwon Roh, Kang Soo Lee, Songhwa Choi & Jae-Min Kim. (2022) Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study. Clinical Psychopharmacology and Neuroscience 20:3, pages 548-559.
Crossref
Crossref
Weifeng Mi, Fude Yang, Huafang Li, Xiufeng Xu, Lehua Li, Qingrong Tan, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Jielai Xia, Kai Yuan, Lin Lu, Jiahui Deng, Jingwei Tian & Hongyan Zhang. (2022) Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. International Journal of Neuropsychopharmacology 25:3, pages 252-260.
Crossref
Crossref
Saritha Ch, Sree Sudha, C. Gowtham Reddy, Pugazhenthan T, Krishna Sasanka KSBS, Pooja Dasari, Pradeep Battula, Nandini T & Sandeep A. (2022) A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression. Cureus.
Crossref
Crossref
Erick H. Turner, Andrea Cipriani, Toshi A. Furukawa, Georgia Salanti & Ymkje Anna de Vries. (2022) Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLOS Medicine 19:1, pages e1003886.
Crossref
Crossref
Lena Rink, Anne Adams, Cora Braun, Tom Bschor, Kathrin Kuhr & Christopher Baethge. (2022) Dose-Response Relationship in Selective Serotonin and Norepinephrine Reuptake Inhibitors in the Treatment of Major Depressive Disorder: A Meta-Analysis and Network Meta-Analysis of Randomized Controlled Trials. Psychotherapy and Psychosomatics 91:2, pages 84-93.
Crossref
Crossref
Sigal Zilcha-Mano, Xuemei Wang, Dalia B. Wajsbrot, Matthieu Boucher, Stuart A. Fine & Bret R. Rutherford. (2021) Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials. Journal of Clinical Psychopharmacology 41:5, pages 579-584.
Crossref
Crossref
Anna Calvi, Ilaria Fischetti, Ignazio Verzicco, Martino Belvederi Murri, Stamatula Zanetidou, Riccardo Volpi, Pietro Coghi, Stefano Tedeschi, Mario Amore & Aderville Cabassi. (2021) Antidepressant Drugs Effects on Blood Pressure. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Sarah E Hetrick, Joanne E McKenzie, Alan P Bailey, Vartika Sharma, Carl I Moller, Paul B Badcock, Georgina R Cox, Sally N Merry & Nicholas Meader. (2021) New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database of Systematic Reviews 2021:5.
Crossref
Crossref
Claudio N. Soares, Dalia B. Wajsbrot & Matthieu Boucher. (2019) Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder. CNS Spectrums 25:3, pages 363-371.
Crossref
Crossref
Martin A Katzman, Xuemei Wang, Dalia B Wajsbrot & Matthieu Boucher. (2020) Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. Journal of Psychopharmacology 34:3, pages 280-292.
Crossref
Crossref
Fenghua Li, Madeeha Nasir, Baris Olten & Michael H. Bloch. (2020) Meta-analysis of placebo group dropout in adult antidepressant trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry 98, pages 109777.
Crossref
Crossref
Danilo Carrozzino, Chiara Patierno, Giovanni A. Fava & Jenny Guidi. (2020) The Hamilton Rating Scales for Depression: A Critical Review of Clinimetric Properties of Different Versions. Psychotherapy and Psychosomatics 89:3, pages 133-150.
Crossref
Crossref
Mark Zimmerman, Caroline Balling, Iwona Chelminski & Kristy Dalrymple. (2020) Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications. Journal of Affective Disorders 260, pages 483-488.
Crossref
Crossref
Claudio N. Soares, Min Zhang & Matthieu Boucher. (2017) Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. CNS Spectrums 24:03, pages 322-332.
Crossref
Crossref
Tina H. Byun, Swarna S. Chaliki & Kenneth G. PooleJrJr. (2019) New Treatment Options for Depression: A Primer for Internists. The American Journal of Medicine 132:6, pages 678-684.
Crossref
Crossref
Esther Alonso-Prieto, Cristina Rubino, Megan Lucey, Vanessa C. Evans, Edwin M. Tam, Cindy Woo, Grant L. Iverson, Trisha Chakrabarty, Lakshmi N. Yatham & Raymond W. Lam. (2019) Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine. Psychiatry Research 272, pages 144-148.
Crossref
Crossref
Shivananda Manohar J., Arpit Koolwal & T. S. Sathyanarayana Rao. (2019) Sex and Depression. Journal of Psychosexual Health 1:1, pages 52-56.
Crossref
Crossref
Kiley Cappetta, Chad Beyer, Jessica A. Johnson & Michael H. Bloch. (2018) Meta-analysis: Risk of dry mouth with second generation antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 84, pages 282-293.
Crossref
Crossref
Maria Bogdan, Eliza Gofita, Daniela Cornelia Calina, Adina Turcu-Stiolica, Anca Oana Docea, Tudor Adrian Balseanu, Adrian Camen, Gratiela Eliza Popa, Gabriela Rusu, Ina Cristofor, Liliana Pavel & Liliana Mititelu-Tartau. 2018. Pharmacokinetics and Adverse Effects of Drugs - Mechanisms and Risks Factors. Pharmacokinetics and Adverse Effects of Drugs - Mechanisms and Risks Factors.
Alice I. Nichols, Sam Liao & Richat Abbas. (2018) Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations. Clinical Pharmacology in Drug Development 7:4, pages 441-450.
Crossref
Crossref
W. Gordon Frankle, Brigitte Robertson, Gary Maier, Jennifer Paris, Deanna Asmonga, Maureen May, Michael L. Himes, N. Scott Mason, Chester A. Mathis & Rajesh Narendran. (2018)
An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (
R
)-(-)-
O
-desmethylvenlafaxine and racemic
O
-desmethylvenlafaxine
. Synapse 72:3, pages e22021.
Crossref
Crossref
Karen L. WeihsWilliam MurphyRichat AbbasDeborah ChilesRichard D. EnglandSara RamakerDalia B. Wajsbrot. (2018) Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder. Journal of Child and Adolescent Psychopharmacology 28:1, pages 36-46.
Crossref
Crossref
Chad Beyer, Kiley Cappetta, Jessica A. Johnson & Michael H. Bloch. (2017) Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants. Depression and Anxiety 34:12, pages 1134-1146.
Crossref
Crossref
David Sarfati, Vanessa C. Evans, Edwin M. Tam, Cindy Woo, Grant L. Iverson, Lakshmi N. Yatham & Raymond W. Lam. (2017) The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine. International Clinical Psychopharmacology 32:6, pages 343-349.
Crossref
Crossref
Martin A. KatzmanAndrew A. NierenbergDalia B. WajsbrotEllen MeierRita PrietoElizabeth PappadopulosJoan MackellMatthieu Boucher. (2017) Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology 37:5, pages 555-561.
Crossref
Crossref
Lesley J. Scott. (2017) Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use. Drugs & Therapy Perspectives 33:10, pages 449-454.
Crossref
Crossref
Raymond W Lam, Dalia B Wajsbrot, Ellen Meier, Elizabeth Pappadopulos, Joan A Mackell & Matthieu Boucher. (2017) Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis. Journal of Psychopharmacology 31:9, pages 1204-1214.
Crossref
Crossref
Daniel MoscaMin ZhangRita PrietoMatthieu Boucher. (2017) Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline. Journal of Clinical Psychopharmacology 37:2, pages 182-192.
Crossref
Crossref
Andy Wolff, Revan Kumar Joshi, Jörgen Ekström, Doron Aframian, Anne Marie Lynge Pedersen, Gordon Proctor, Nagamani Narayana, Alessandro Villa, Ying Wai Sia, Ardita Aliko, Richard McGowan, Alexander Ross Kerr, Siri Beier Jensen, Arjan Vissink & Colin Dawes. (2016) A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs in R&D 17:1, pages 1-28.
Crossref
Crossref
N. Timmerby, J.H. Andersen, S. Søndergaard, S.D. Østergaard & Per Bech. (2017) A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D<sub>6</sub>). Psychotherapy and Psychosomatics 86:3, pages 141-149.
Crossref
Crossref
Raymond W. Lam, Grant L. Iverson, Vanessa C. Evans, Lakshmi N. Yatham, Kurtis Stewart, Edwin M. Tam, Auby Axler & Cindy Woo. (2016) The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. Journal of Affective Disorders 203, pages 55-61.
Crossref
Crossref
Sujana Reddy, Rana Fayyad, Chris J Edgar, Christine J Guico-Pabia & Keith Wesnes. (2016) The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology 30:6, pages 559-567.
Crossref
Crossref
José L. Carrasco, Susan G. Kornstein, Roger S. McIntyre, Rana Fayyad, Rita Prieto, Maribel Salas, Joan Mackell & Matthieu Boucher. (2016) An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. International Clinical Psychopharmacology 31:3, pages 134-146.
Crossref
Crossref
Vanessa C. Evans, Golnoush Alamian, Jane McLeod, Cindy Woo, Lakshmi N. Yatham & Raymond W. Lam. (2016) The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CNS Drugs 30:5, pages 405-417.
Crossref
Crossref
Javier Rejas Gutiérrez, Milagrosa Blanca Tamayo, Josep Gascón Barrachina & Beatriz Armada Peláez. (2016) Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain. Revista de Psiquiatría y Salud Mental (English Edition) 9:2, pages 87-96.
Crossref
Crossref
Javier Rejas Gutiérrez, Milagrosa Blanca Tamayo, Josep Gascón Barrachina & Beatriz Armada Peláez. (2016) Evaluación económica de la desvenlafaxina en el tratamiento de la depresión mayor en España. Revista de Psiquiatría y Salud Mental 9:2, pages 87-96.
Crossref
Crossref
Mark Zimmerman, Heather L. Clark, Matthew D. Multach, Emily Walsh, Lia K. Rosenstein & Douglas Gazarian. (2016) Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. Journal of Affective Disorders 190, pages 357-361.
Crossref
Crossref
R. Ghosh, R. Gupta, M.S. Bhatia, A.K. Tripathi & L.K. Gupta. (2015) Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine. Asian Journal of Psychiatry 18, pages 37-41.
Crossref
Crossref
Anita H. Clayton, Eunhee Hwang, Susan G. Kornstein, Karen A. Tourian, Ru-fong Cheng, Lucy Abraham, Linda Mele & Matthieu Boucher. (2015) Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder. International Clinical Psychopharmacology 30:6, pages 307-315.
Crossref
Crossref
Per Bech. (2015)
The responsiveness of the different versions of the
H
amilton Depression Scale
. World Psychiatry 14:3, pages 309-310.
Crossref
Crossref
Claudio N. Soares, Jean Endicott, Matthieu Boucher, Rana S. Fayyad & Christine J. Guico-Pabia. (2014) Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectrums 19:6, pages 519-527.
Crossref
Crossref
Mandy Malick, Kim Gilbert, Mathieu Barry, Roger Godbout & Guy Rousseau. (2014) Desvenlafaxine reduces apoptosis in amygdala after myocardial infarction. Brain Research Bulletin 109, pages 158-163.
Crossref
Crossref
Susan G. Kornstein, Christine J. Guico-Pabia & Rana S. Fayyad. (2014) The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies. Human Psychopharmacology: Clinical and Experimental 29:5, pages 492-501.
Crossref
Crossref
Susan G. Kornstein, Anita Clayton, Weihang Bao & Christine J. Guico-Pabia. (2014) Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Menopause 21:8, pages 799-806.
Crossref
Crossref
Robert L. FindlingJames GroarkDeborah ChilesSara RamakerLingfeng YangKaren A. Tourian. (2014) Safety and Tolerability of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder. Journal of Child and Adolescent Psychopharmacology 24:4, pages 201-209.
Crossref
Crossref
Claudio N. Soares, Rana S. Fayyad & Christine J. Guico-Pabia. (2014) Early Improvement in Depressive Symptoms With Desvenlafaxine 50 mg/d as a Predictor of Treatment Success in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology 34:1, pages 57-65.
Crossref
Crossref
Michelle D. Colvard. (2014) Key differences between Venlafaxine XR and Desvenlafaxine: An analysis of pharmacokinetic and clinical data. Mental Health Clinician 4:1, pages 35-39.
Crossref
Crossref
Michael R Liebowitz, Karen A Tourian, Eunhee Hwang & Linda Mele. (2013) A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry 13:1.
Crossref
Crossref
J. Song, J. Yin & J. D. Z. Chen. (2013) Acute and chronic effects of desvenlafaxine on gastrointestinal transit and motility in dogs. Neurogastroenterology & Motility, pages n/a-n/a.
Crossref
Crossref
NAKAO IWATA, KAREN A. TOURIAN, EUNHEE HWANG, LINDA MELE & CECILE VIALET. (2013) Efficacy and Safety of Desvenlafaxine 25 and 50 Mg/Day in a Randomized, Placebo-Controlled Study of Depressed Outpatients. Journal of Psychiatric Practice 19:1, pages 5-14.
Crossref
Crossref
Narcís Cardoner Álvarez. (2013) Desvenlafaxina, un nuevo IRSN para el tratamiento de la depresión mayor: Revisión de la literatura. Psiquiatría Biológica 20:1-2, pages 2-7.
Crossref
Crossref
Kristina A. Coleman, Vanessa Y. Xavier, Trish L. Palmer, James V. Meaney, Libby M. Radalj & Louise M. Canny. (2012) An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectrums 17:3, pages 131-141.
Crossref
Crossref
James M. Ferguson, Karen A. Tourian & Gregory R. Rosas. (2012) High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectrums 17:3, pages 121-130.
Crossref
Crossref
Juan Undurraga & Ross J Baldessarini. (2011) Randomized, Placebo-Controlled Trials of Antidepressants for Acute Major Depression: Thirty-Year Meta-Analytic Review. Neuropsychopharmacology 37:4, pages 851-864.
Crossref
Crossref
Fei Dai, Yong Lei & Jiande D. Z. Chen. (2011) Inhibitory effects of desvenlafaxine on gastric slow waves, antral contractions, and gastric accommodation mediated via the sympathetic mechanism in dogs. American Journal of Physiology-Gastrointestinal and Liver Physiology 301:4, pages G707-G712.
Crossref
Crossref
Mathias B Forrester & C Lizette Villarreal. (2011) Comparison of Desvenlafaxine and Venlafaxine Ingestions Reported to Texas Poison Centers. Journal of Pharmacy Technology 27:1, pages 35-40.
Crossref
Crossref
Karen A. Tourian, Krishna Padmanabhan, Jim Groark & Philip T. Ninan. (2010) Retrospective Analysis of Suicidality in Patients Treated With the Antidepressant Desvenlafaxine. Journal of Clinical Psychopharmacology 30:4, pages 411-416.
Crossref
Crossref
Claudio N. Soares, Michael E. Thase, Anita Clayton, Christine J. Guico-Pabia, Kristen Focht, Qin Jiang, Susan G. Kornstein, Phil Ninan, Cecelia P. Kane & Lee S. Cohen. (2010) Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 17:4, pages 700-711.
Crossref
Crossref
Susan G. Kornstein, Anita H. Clayton, Claudio N. Soares, Sudharshan K. Padmanabhan & Christine J. Guico-Pabia. (2010) Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder. Journal of Clinical Psychopharmacology 30:3, pages 294-299.
Crossref
Crossref
Karen A. Tourian, Qin Jiang & Philip T. Ninan. (2014) Analysis of the Effect of Desvenlafaxine on Anxiety Symptoms Associated with Major Depressive Disorder: Pooled Data from 9 Short-Term, Double-blind, Placebo-Controlled Trials. CNS Spectrums 15:3, pages 187-193.
Crossref
Crossref
Antolin C. TrinidadBenjamin Bregman. (2010) Pharmacotherapy of Major Depressive Disorder: Focus on Desvenlafaxine Succinate. Clinical Medicine Insights: Therapeutics 2, pages CMT.S74.
Crossref
Crossref
Stuart A. Montgomery, Maurizio Fava, Sudharshan K. Padmanabhan, Christine J. Guico-Pabia & Karen A. Tourian. (2009) Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. International Clinical Psychopharmacology 24:6, pages 296-305.
Crossref
Crossref
Debra W. KempJamie N. BrownToyin S. Tofade. (2009) Recent Advances in Pharmacotherapy. Journal of Pharmacy Practice 22:5, pages 446-466.
Crossref
Crossref
Alastair H MacLennan. (2009) Evidence-based review of therapies at the menopause. International Journal of Evidence-Based Healthcare 7:2, pages 112-123.
Crossref
Crossref
Sidney H. Kennedy & Sakina Rizvi. (2009) Sexual Dysfunction, Depression, and the Impact of Antidepressants. Journal of Clinical Psychopharmacology 29:2, pages 157-164.
Crossref
Crossref
Anita H. Clayton, Susan G. Kornstein, Gregory Rosas, Christine Guico-Pabia & Karen A. Tourian. (2014) An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder. CNS Spectrums 14:4, pages 183-195.
Crossref
Crossref
Michael E. Thase, Susan G. Kornstein, Jean-Michel Germain, Qin Jiang, Christine Guico-Pabia & Philip T. Ninan. (2014) An Integrated Analysis of the Efficacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder. CNS Spectrums 14:3, pages 144-154.
Crossref
Crossref
David F. Archer, Caroline M. Dupont, Ginger D. Constantine, James H. Pickar & Sophie Olivier. (2009) Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. American Journal of Obstetrics and Gynecology 200:3, pages 238.e1-238.e10.
Crossref
Crossref
David F. Archer, Larry Seidman, Ginger D. Constantine, James H. Pickar & Sophie Olivier. (2009) A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. American Journal of Obstetrics and Gynecology 200:2, pages 172.e1-172.e10.
Crossref
Crossref
Pedro Luis Dago. (2014) Factors That Impact Choice of Antidepressant Treatment in Medically Complex Patients. CNS Spectrums 14:S12, pages 20-27.
Crossref
Crossref
Lawrence D. Ginsberg. (2014) Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder. CNS Spectrums 14:S12, pages 8-14.
Crossref
Crossref
Mark Zimmerman. (2014) Introduction: Selecting an Antidepressant. CNS Spectrums 14:S12, pages 4-7.
Crossref
Crossref
Alan D. Feiger, Karen A. Tourian, Gregory R. Rosas & S. Krishna Padmanabhan. (2014) A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder. CNS Spectrums 14:1, pages 41-50.
Crossref
Crossref
Richard Perry & Manouchkathe Cassagnol. (2009) Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clinical Therapeutics 31, pages 1374-1404.
Crossref
Crossref
Karen A. Tourian, S. Krishna Padmanabhan, James Groark, Claudine Brisard & Deborah Farrington. (2009) Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clinical Therapeutics 31, pages 1405-1423.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:1.
Crossref
Crossref
Albena Patroneva, Sandra M. Connolly, Penny Fatato, Ron Pedersen, Qin Jiang, Jeffrey Paul, Christine Guico-Pabia, Jennifer A. Isler, Michael E. Burczynski & Alice I. Nichols. (2008) An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects. Drug Metabolism and Disposition 36:12, pages 2484-2491.
Crossref
Crossref
Patrice Boyer, Stuart Montgomery, Ulla Lepola, Jean-Michel Germain, Claudine Brisard, Rita Ganguly, Sudharshan K. Padmanabhan & Karen A. Tourian. (2008) Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. International Clinical Psychopharmacology 23:5, pages 243-253.
Crossref
Crossref
Weifeng Mi, Fude Yang, Huafang Li, Xiufeng Xu, Lehua Li, Qingrong Tan, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Jielai Xia, Kai Yuan, Lin Lu, Jiahui Deng, Jingwei Tian & Hongyan Zhang. (2021) Efficacy, Safety, and Tolerability of Ansofaxine (Ly03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo Controlled, Dose-Finding, Phase 2 Clinical Trial. SSRN Electronic Journal.
Crossref
Crossref